A61K31/4045

TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING VALENTONIN AND USE THEREOF AS A MEDICAMENT

The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).

TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING VALENTONIN AND USE THEREOF AS A MEDICAMENT

The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).

TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING VALENTONIN AND USE THEREOF AS A MEDICAMENT

The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).

Compositions for Preventing and Treating Pulmonary Injury due to Ionizing Radiation or Cytotoxic Drugs
20180000781 · 2018-01-04 ·

Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.

Compositions for Preventing and Treating Pulmonary Injury due to Ionizing Radiation or Cytotoxic Drugs
20180000781 · 2018-01-04 ·

Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.

Compositions for Preventing and Treating Pulmonary Injury due to Ionizing Radiation or Cytotoxic Drugs
20180000781 · 2018-01-04 ·

Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.

COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN
20180000766 · 2018-01-04 ·

An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

COMPOSITIONS COMPRISING MAGNOLIA, PHELLODENDRON, THEANINE AND/OR WHEY PROTEIN
20180000766 · 2018-01-04 ·

An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Disclosed are novel C.sub.4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Disclosed are novel C.sub.4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.